Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer
Interventions: DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Pembrolizumab|DRUG: Pegfilgrastim
Sponsor: University of Kansas Medical Center
Collaborators: Merck Sharp & Dohme LLC